Cardiff Oncology CEO buys 24,703 shares

Cardiff Oncology CEO Mani Mohindru reported an open-market purchase of 24,703 shares of Common Stock at $1.21 per share.

Rhea-AI Filing Summary

Cardiff Oncology CEO Mani Mohindru reported an open-market purchase of 24,703 shares of Common Stock at $1.21 per share. This transaction took place on June 18, 2026 and represents a direct holding. Following the trade, her reported direct ownership totals 24,703 shares.

Insights

Equity governance analyst

CEO completed a modest open-market share purchase, signaling personal equity exposure.

The filing shows Chief Executive Officer Mani Mohindru executed an open-market purchase of 24,703 shares of Cardiff Oncology Common Stock at $1.21 per share. The transaction is coded as a standard purchase (P), not a grant or option exercise.

After this trade, her reported direct holdings equal 24,703 shares, with no derivative positions listed. The size appears relatively small in absolute terms, and no Rule 10b5-1 trading plan is referenced in the provided data, suggesting a discretionary transaction but with limited visible scale.

Insider Trade Summary

Net Buyer: 24,703 shares

Net Buy 1 txn

Insider Mohindru Mani

Role Chief Executive Officer

Bought 24,703 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	24,703	$1.21	$30K

Holdings After Transaction: Common Stock — 24,703 shares (Direct)

Key Figures

Shares purchased: 24,703 shares Purchase price: $1.21 per share Direct holdings after transaction: 24,703 shares +1 more

4 metrics

Shares purchased 24,703 shares Open-market purchase of Common Stock on June 18, 2026

Purchase price $1.21 per share Price for CEO’s open-market buy

Direct holdings after transaction 24,703 shares Total Common Stock directly owned by CEO after trade

Net buy shares 24,703 shares Net buy direction in transaction summary

Key Terms

open-market purchase, Common Stock, transaction code "P"

3 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code "P" financial

""transaction_code": "P""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardiff Oncology (CRDF) report for its CEO?

Cardiff Oncology reported that CEO Mani Mohindru bought 24,703 shares of Common Stock in an open-market transaction. The shares were purchased at $1.21 each, and the filing classifies the trade as a standard purchase transaction coded “P.”

How many Cardiff Oncology (CRDF) shares does the CEO hold after this Form 4?

Following the reported transaction, CEO Mani Mohindru directly holds 24,703 shares of Cardiff Oncology Common Stock. The Form 4 shows this as her total direct ownership, with no additional derivative positions disclosed in the provided data excerpt.

At what price did the Cardiff Oncology (CRDF) CEO buy shares?

The CEO’s open-market purchase was executed at $1.21 per share. In total, 24,703 shares of Cardiff Oncology Common Stock were acquired at this price according to the Form 4 insider transaction report filed for June 18, 2026.

Was the Cardiff Oncology (CRDF) CEO’s transaction a purchase or sale?

The transaction was a purchase. The Form 4 classifies it as an open-market purchase with transaction code “P,” and the normalized data labels the direction as a buy, not a sale or derivative exercise, for 24,703 shares of Common Stock.

Does the Cardiff Oncology (CRDF) Form 4 show any options or derivatives for the CEO?

The provided Form 4 data shows no derivative transactions or remaining derivative positions for the CEO. The derivativeSummary section is empty, and the only reported activity is the direct purchase of 24,703 Common Stock shares on June 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 09:00 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohindru Mani

(Last) (First) (Middle)

11055 FLINTKOTE AVENUE

C/O CARDIFF ONCOLOGY, INC.

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		P		24,703	A	$1.21	24,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Mani Mohindru	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)